Hutchmed China Ltd ADR (NQ: HCM )

19.19 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist

Price and Volume

Volume	52
Open	19.19
Bid (Size)	18.20 (1)
Ask (Size)	19.15 (1)
Prev. Close	19.19
Today's Range	19.19 - 19.19
52wk Range	11.93 - 21.92
Shares Outstanding	871,256,270
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why HUTCHMED Stock Is Moving Higher Friday

July 05, 2024

HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.

Via Benzinga

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

July 03, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Performance

YTD	+9.59%	+9.59%
1 Month	+7.75%	+7.75%
3 Month	+17.30%	+17.30%
6 Month	+25.59%	+25.59%
1 Year	+57.30%	+57.30%

More News

HUTCHMED to Announce 2024 Half-Year Financial Results

June 26, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

June 24, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

June 21, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

June 16, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

June 06, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

June 02, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

May 23, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

May 17, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

May 16, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

May 13, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

May 13, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday

May 09, 2024

Via Benzinga

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

May 08, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

April 26, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion

April 06, 2024

Via Talk Markets

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

April 05, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

April 02, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

March 27, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

March 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

March 13, 2024

Via Benzinga

Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket

March 13, 2024

Via Benzinga

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

March 13, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

March 13, 2024

Via InvestorPlace

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.